Aging Impairs CAR-T Cell Therapy Effectiveness Through Metabolic Decline, Swiss Study Reveals

Swiss researchers have uncovered a critical link between aging and the diminished effectiveness of CAR-T cell therapy (搜索)搜索该药品, one of the most advanced forms of cancer (搜索)搜索该疾病 immunotherapy. The collaborative study, conducted by teams from the University of Lausanne查看公司主页 (UNIL), Lausanne University Hospital查看公司主页 (CHUV), Geneva University Hospitals (搜索)搜索该词条 (HUG), and the Ecole Polytechnique Fédérale de Lausanne查看公司主页 (EPFL), reveals how age-related metabolic changes compromise the therapeutic potential of engineered immune cells.

CAR-T therapy involves extracting a patient's T cells, genetically modifying them to recognize and attack cancer (搜索)搜索该疾病 cells, and then reinfusing them into the patient. While this approach has shown remarkable success in certain cancers, its efficacy in older patients has been less consistent.

Age-Related Metabolic Decline Affects CAR-T Function

The research team found that CAR-T cells derived from aged mice exhibited significant functional impairments compared to those from younger subjects. These aged cells demonstrated poor mitochondrial function, reduced "stemness" (the ability to self-renew and differentiate), and markedly decreased antitumor activity.

At the molecular level, researchers identified a substantial drop in nicotinamide adenine dinucleotide查看药品详情 (NAD查看药品详情) levels as the primary culprit. NAD is a crucial molecule that plays a central role in cellular energy production and mitochondrial metabolism.

"CAR-T cells from older individuals are metabolically impaired and significantly less effective," explained Dr. Helen Carrasco Hope, one of the study's researchers. "What's exciting is that we were able to rejuvenate these aged cells by restoring their NAD查看药品详情 levels — reviving their antitumor function in preclinical models."

Implications for Cancer Treatment in Aging Populations

This discovery has significant implications for cancer (搜索)搜索该疾病 treatment, particularly as most cancer patients are older adults. The immune system naturally deteriorates with age, a process known as immunosenescence (搜索)搜索该疾病, which can make immunotherapies less effective precisely in the population that needs them most.

The findings highlight a critical gap in current preclinical research models, which often fail to account for age-related factors when developing new therapies.

"Our findings strengthen the growing recognition that aging fundamentally reshapes immune cell function and metabolism," Dr. Hope noted. "They highlight the urgent need to model age more accurately in preclinical studies so that therapies are developed with the real-world cancer (搜索)搜索该疾病 population in mind — where most patients are older adults."

Potential for Metabolic Intervention

The most promising aspect of the study is the demonstration that age-related CAR-T cell impairment may be reversible. By restoring NAD查看药品详情 levels in aged CAR-T cells, researchers were able to rejuvenate their antitumor function in laboratory models.

This suggests that metabolic interventions targeting NAD查看药品详情 pathways could potentially enhance the efficacy of CAR-T therapy in older cancer (搜索)搜索该疾病 patients. Such approaches might include NAD precursor supplementation or other strategies to boost cellular metabolism.

The research represents an important step toward developing more effective cancer (搜索)搜索该疾病 immunotherapies for aging populations and underscores the importance of considering age-related factors in cancer treatment development. As the global population continues to age, addressing these age-specific challenges in cancer therapy becomes increasingly critical for improving patient outcomes.